Comprehensive Adverse Effects of Metoprolol
Metoprolol causes a broad spectrum of adverse effects across multiple organ systems, with the most common being tiredness and dizziness (occurring in approximately 10% of patients), followed by bradycardia and hypotension (approximately 3% each), and diarrhea (approximately 5%). The FDA drug label provides the most authoritative source for adverse event frequencies 1.
Most Common Adverse Effects by System
Central Nervous System (Very Common to Common)
- Tiredness and dizziness: ~10% of patients 1
- Depression: ~5% of patients 1
- Mental confusion and short-term memory loss (frequency not specified) 1
- Headache, nightmares, and insomnia (frequency not specified) 1
- Sleep disturbances have been reported in clinical trials 2
Cardiovascular Effects (Common)
- Bradycardia: ~3% of patients in general use 1
- Shortness of breath: ~3% of patients 1
- Hypotension: ~1% of patients in general use 1
- Cold extremities: ~1% 1
- Arterial insufficiency (Raynaud type): ~1% 1
- Palpitations: ~1% 1
- Congestive heart failure: ~1% 1
- Peripheral edema: ~1% 1
Respiratory Effects (Common)
Gastrointestinal Effects (Common)
- Diarrhea: ~5% of patients 1
- Nausea, dry mouth, gastric pain, constipation, flatulence, heartburn: ~1% each 1
- Vomiting was noted as a "common occurrence" 1
Dermatologic/Hypersensitivity (Common)
Rare but Serious Adverse Effects
- Peyronie's disease: <1 in 100,000 patients 1
- Reversible alopecia (rare) 1
- Agranulocytosis (rare) 1
- Dry eyes (rare) 1
- Weight gain (very rare) 1
- Arthritis (very rare) 1
- Retroperitoneal fibrosis (very rare, relationship uncertain) 1
- Hepatitis, jaundice, and hepatic dysfunction (very rare in postmarketing) 1
- Gangrene in patients with pre-existing severe peripheral circulatory disorders (very rarely) 1
Metabolic Effects
- Unstable diabetes (frequency unclear, relationship uncertain) 1
- Increase in blood triglycerides and decrease in HDL (postmarketing) 1
Dose-Dependent and Context-Specific Adverse Effects
Perioperative/High-Dose Context
The POISE trial, which used aggressive dosing (metoprolol succinate 100 mg pre-op, 100 mg within 6 hours post-op, then 200 mg daily for 30 days), revealed significantly higher rates of dose-dependent adverse effects 3, 4:
- Hypotension (systolic BP <90 mmHg): 27.4% (vs 23.2% placebo) in myocardial infarction patients 1
- Bradycardia (heart rate <40 bpm): 15.9% (vs 6.7% placebo) 1
- Stroke: 1.0% (vs 0.5% placebo; HR 2.17, p=0.0053) 3
- Death: 3.1% (vs 2.3% placebo; HR 1.33, p=0.0317) 3
- Second- or third-degree heart block: 4.7% 1
- First-degree heart block (P-R ≥0.26 sec): 5.3% (vs 1.9% placebo) 1
Critical caveat: The POISE trial's aggressive dosing without adequate titration and the requirement to continue despite hypotension led to these elevated rates. Post-hoc analysis showed hypotension had the largest attributable risk for death and stroke 3, 5. This underscores that rapid up-titration and high doses without individualized heart rate/blood pressure monitoring substantially increase serious adverse event risk.
Heart Failure Context
In heart failure trials with more gradual titration, adverse event profiles differed 2, 6:
- Fatigue: 7.1-12.6% (varied by study)
- Dizziness: 5.5-12%
- Bradycardia: 0.1-15.9% (depending on context and definition)
- Hypotension: generally asymptomatic in most heart failure trials
- Dyspnea: 18.6-25.4%
- Discontinuation due to adverse events: 8.3-13.7% 2
Vascular Surgery Context
The MaVS trial showed 7:
- Intraoperative bradycardia requiring treatment: 21.5% (53/246) vs 7.6% placebo (p=0.00001)
- Intraoperative hypotension requiring treatment: 46.3% (114/246) vs 33.6% placebo (p=0.0045)
Emerging Safety Signals from Pharmacovigilance
Recent FAERS database analysis identified unexpected adverse reactions 8:
- Orthostatic intolerance (IC025 = 3.00)
- Trigemino-cardiac reflex (IC025 = 4.30)
- Decorticate posture (IC025 = 3.34)
- Suspected suicide (IC025 = 5.59) - notably strong signal requiring attention
Proarrhythmic Potential
In patients with idiopathic frequent monomorphic PVCs, metoprolol showed a "proarrhythmic" response (>50% increase in PVC burden) in 25.3% of patients, particularly those with lower baseline PVC burden (≤10%) 9. This highlights that beta-blockers are not universally antiarrhythmic and can paradoxically worsen certain arrhythmias.
Drug Interaction-Related Adverse Effects
CYP2D6 inhibitors dramatically increase metoprolol exposure and adverse effects 10:
- Strong inhibitors (paroxetine, fluoxetine): up to 8-fold increase in metoprolol exposure
- Moderate inhibitors (mirabegron, amiodarone): 2-3-fold increase
- This leads to phenoconversion, causing extensive metabolizers to experience adverse effects typical of poor metabolizers
- Severe bradycardia and hypotension occur particularly when strong inhibitors are combined with metoprolol in patients with cardiovascular disease and reduced CYP2D6 function 10
Discontinuation Rates
- General use: 6.7% discontinued due to adverse effects 11
- Heart failure trials: 8.3-13.7% discontinued 2
- Perioperative high-dose: higher discontinuation rates due to hemodynamic instability 3
Key Clinical Pitfalls
Rapid titration without monitoring: The POISE trial demonstrated that aggressive dosing (reaching 400 mg/day within 24 hours) without adequate blood pressure/heart rate monitoring leads to excess mortality and stroke 3, 5.
Ignoring CYP2D6 interactions: Co-administration with strong CYP2D6 inhibitors can increase metoprolol levels 8-fold, causing severe bradycardia and hypotension 10.
Assuming universal benefit in arrhythmias: Metoprolol can be proarrhythmic in 25% of patients with certain PVC patterns 9.
Overlooking psychiatric effects: The strong signal for suspected suicide in pharmacovigilance data warrants monitoring for mood changes 8.
Peripheral vascular disease: Gangrene can occur in patients with pre-existing severe peripheral circulatory disorders 1.